Docoh
Loading...

51 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
dose trial. PCS499, an oral tablet of a deuterated analog of one of the major metabolites of pentoxifylline (PTX or Trental®), is classified by FDA
10-Q
2021 Q1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
PPP-related debt is classified as a current liability on our consolidated balances sheet. Note 7 – Stockholders’ Equity On January 11, 2021, we … of one of the major metabolites of pentoxifylline (PTX or Trental®). PCS499 is classified by FDA as a new molecular entity. PCS499 and its metabolites act
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
tablet that is a deuterated analog of one of the major metabolites of pentoxifylline (PTX or Trental®). PCS499 is classified by FDA as a new molecular … , 2020, $117,574 of the total $162,459 PPP-related debt is classified as a current liability on our consolidated balances sheet. F-18 Note 9
10-Q
2020 Q3
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
in whole or in part. As of September 30, 2020, $90,329 of the total $162,459 PPP-related debt is classified as a current liability on our condensed … or Trental®). PCS499 is classified by FDA as a new molecular entity. PCS499 and its metabolites act on multiple pharmacological targets that are important
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
or Trental®). PCS499 is classified by FDA as a new molecular entity. PCS499 and its metabolites act on multiple pharmacological targets … enactment. SAB 118 provides for tax amounts to be classified as provisional and subject to remeasurement for up to one year from the enactment date
S-1/A
i9m x0lq8kac
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
zr7d w1zrf2jhi
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-2.1
mml2dof0wof5cfe
16 Sep 20
IPO registration (amended)
8:00pm
10-Q
qty23
5 Aug 20
Quarterly report
3:32pm
S-1/A
h53k1a7t
17 Jul 20
IPO registration (amended)
5:25pm
10-K
5uaz0xxus
5 Mar 20
Annual report
7:00pm
S-1
6w6up9e4g5wnu8 1w1r
13 Dec 19
IPO registration
5:32pm
10-K/A
i19acm
5 Apr 19
Annual report (amended)
9:40pm
10-K
0m7 4vyduxb
28 Mar 19
Annual report
5:25pm
424B3
lvwr5snkwuza2pgzj
13 Nov 18
Prospectus supplement
9:39pm
10-Q
hvemd2 5a87uyx
13 Nov 18
Quarterly report
9:37pm
424B3
2srrndcstld93zg hha
9 Nov 18
Prospectus supplement
5:04pm
S-1/A
hunpftg mfkbku8v1kt
30 Oct 18
IPO registration (amended)
4:19pm
S-1/A
qcl vhkxncnor3ae6bh
9 Oct 18
IPO registration (amended)
5:32pm
S-1/A
bb36n38
13 Sep 18
IPO registration (amended)
8:00pm